Advertisement
open access
Medical Conferences

Medical Conferences

  • Conference Reports
    • 2023 Medicom Conference Planning
  • Disease Areas
  • Other Medical News
  • Podcast
  • Videos
  • Education
  • About
    • Vacancies

Tag: STAMPEDE

Overall survival benefit of abiraterone in mHSPC is maintained for 7 years

Presented By
Prof. Gerhardt Attard, UCL Cancer Institute London, UK
Trial
Phase 3, STAMPEDE
Conference
ESMO 2022

17 November, 2022 00:23

Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment

Trial
Phase 3, PEACE-1, STAMPEDE, ARCHES
Conference
ESMO 2021

19 November, 2021 09:27

Abiraterone in M1 hormone-naïve prostate cancer

Conference
ESMO 2020

25 November, 2020 14:51

Prostate cancer: What to expect the next 12 months

Trial
STAMPEDE, ENZAMET
Conference
EAU 2019

21 May, 2019 10:27
site created by:   

© 2023 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy